Take a picture: The role of imaging in PAH diagnosis and treatment
23 June 2020 - 53 Minutes

Take a picture: The role of imaging in PAH diagnosis and treatment

As PAH progresses, remodeling of the pulmonary vasculature triggers a chain of events that culminate in structural changes in the right ventricle as it adapts to the elevated vascular resistance and arterial pressures to maintain cardiac output. Imaging techniques such as cardiac MRI and echocardiography can be used to monitor these changes in morphology and function, as well as evaluate ...

more info...

20003426
Evidence-based screening and treatment options for pulmonary arterial hypertension in connective tissue diseases
14 May 2020 - 53 Minutes

Evidence-based screening and treatment options for pulmonary arterial hypertension in connective tissue diseases

Patients with connective tissue disease are at a higher risk for developing PAH, for example an estimated 5-12% of scleroderma patients will develop PAH. Furthermore, the prognosis is poor for these patients; over half of patients with PAH-CTD will die within 5 years of diagnosis.

During this webinar we will discuss the importance of regular ...

more info...

20001141
The myth of stability in PAH: Assessing and treating patients for optimal outcomes
30 April 2020 - 47 Minutes

The myth of stability in PAH: Assessing and treating patients for optimal outcomes

Substantial progress has been made in treating patients with PAH, however the long-term prognosis of patients remains poor. Patients may appear “clinically stable” while their underlying disease is not. While the rate of PAH progression may vary, it is well known today that the pulmonary vasculature and the right heart continue to deteriorate, regardless of initial or current functional class, in ...

more info...

20002749
Help your patients reach their long-term goals: The impact of early treatment choices in PAH
18 February 2020 - 44 Minutes

Help your patients reach their long-term goals: The impact of early treatment choices in PAH

As the number of available PAH-specific therapies has increased, the optimal use of these therapies in clinical management continues to be a hot topic. It is critical to accurately assess a patient’s risk status so that signs of disease progression can be identified and the treatment strategy can be adjusted accordingly. This webinar will highlight the importance ...

more info...

20000324
Timing is critical: When to intensify therapy in PAH
11 November 2019 - 50 Minutes

Timing is critical: When to intensify therapy in PAH

Despite the significant advances made in the field of PAH, challenges remain in the management of this complex disease. Achieving optimal long-term outcomes in PAH requires a timely initiation of an individualized treatment regimen. During this webinar we will discuss how, in the current management era, early intensification of therapy guided by risk assessment plays an important role in improving ...

more info...

Cómo y cuándo iniciar la triple terapia: Consejos prácticos
30 September 2019 - 39 Minutes

Cómo y cuándo iniciar la triple terapia: Consejos prácticos

Please note: this webinar is in Spanish

Objetivos de aprendizaje:

Comprender cuándo es el momento adecuado para iniciar la triple terapia y también aprender a identificar a los pacientes elegidos que podrían beneficiarse, teniendo en cuenta consejos prácticos para obtener el mejor resultado.

 

Faculty:

  • Dra. Pilar Escribano
  • Dr. Tomás Pulido
more info...

EM-17716
PAH in practice: Putting patients first
17 September 2019 - 58 Minutes

PAH in practice: Putting patients first

The faculty will give guidance on which patients are candidates for receiving selexipag, and provide practical insights on how to introduce the drug, especially keeping in mind the benefits for patients and the long-term therapeutic goals. The ‘typical’ patient’s experience with selexipag will be included. 

Learning objective:

- To apply the ...

more info...

PAH in 2019 & beyond: Sharing experiences & real-world data
9 July 2019 - 47 Minutes

PAH in 2019 & beyond: Sharing experiences & real-world data

The faculty will explore real-world data on targeting the prostacyclin pathway in clinical practice, and highlight key features of ongoing studies. Personal experience with the use of selexipag in the management of PAH patients will be shared. 

Learning objective:

- To discuss and explain the new data on the use of therapies targeting the prostacyclin pathway in the real world, including personal ...

more info...

Updates in PAH management: Insights from the 6th WSPH
14 May 2019 - 49 Minutes

Updates in PAH management: Insights from the 6th WSPH

The faculty will discuss multi-parameter risk assessment as recommended by the WSPH proceedings, how relevant risk assessment is for themselves, and what role escalating to double or triple combination therapy plays in their clinical practice. 

Learning objective:

- To reflect upon the relevance of risk stratification in PAH, and the implication ...

more info...